To assess the impact of Cflar reduction on leukemia development in vivo, we performed transplant experiments using CD45.2+ control (Con), Cux1+/−, Flt3ITD or Cux1+/−;Flt3ITD c-Kit+ cells transduced with doxycycline-inducible, Cflar-targeting shRNA lentiviruses along with wild-type CD45.1+CD45.2+ support bone marrow cells into lethally irradiated CD45.1+CD45.2+ recipient mice (Fig. 6h). The gene discussed is CFLAR; the disease is leukemia.